Skip to content
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Contact Us
Schwab Client Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Phathom Pharmaceuticals, Inc. - Common Stock
(NQ:
PHAT
)
5.080
UNCHANGED
Delayed Quote
Updated: 4:00 PM EST, Nov 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Phathom Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
March 26, 2024
National TV and digital media campaign aims to motivate millions of people suffering from Erosive GERD to learn more about VOQUEZNA® (vonoprazan), the first and only FDA-approved potassium-competitive...
From
Phathom Pharmaceuticals
Via
GlobeNewswire
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
↗
March 07, 2024
PHAT stock results show that Phathom Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 07, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Preview: Phathom Pharmaceuticals's Earnings
↗
March 06, 2024
Via
Benzinga
Recap: Phathom Pharmaceuticals Q3 Earnings
↗
November 09, 2023
Via
Benzinga
Earnings Scheduled For March 7, 2024
↗
March 07, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
Via
Benzinga
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
February 29, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Walmart Posts Upbeat Earnings, Joins Armstrong World Industries, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
↗
February 20, 2024
U.S. stocks were mostly lower, with the Nasdaq Composite falling more than 200 points on Tuesday.
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
↗
February 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
February 16, 2024
Via
Benzinga
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
February 13, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
↗
January 05, 2024
Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT),
Via
Benzinga
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
December 14, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
December 06, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
November 28, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
November 09, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
November 01, 2023
Via
Benzinga
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
November 01, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
What's Going On With Phathom Pharmaceuticals Stock?
↗
October 30, 2023
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) shares are trading higher Monday after the company announced FDA approval of its reformulated vo
Via
Benzinga
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
October 30, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
October 25, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Cramer Likes This Industrial Stock: A 'Well-Run' Company Doing 'A Lot Of Good Things'
↗
October 13, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended not buying ChargePoint Holdings, Inc.
Via
Benzinga
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
September 26, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
September 05, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
August 21, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
August 10, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
↗
August 09, 2023
Via
Benzinga
3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now
↗
August 07, 2023
One of the safest sectors on the market is biotech. Here are three cheap biotech stocks to buy that are good options for investors.
Via
InvestorPlace
Bragar Eagel & Squire, P.C. Is Investigating Integra, Chinook, Phathom, and Akumin and Encourages Investors to Contact the Firm
June 19, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
